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Abstract: There is no consensus on the optimal antiviral regimen in the management of acute 
retinal necrosis, a disease caused by herpetic viruses with devastating consequences for the eye. 
The current gold standard is based on retrospective case series. Because the incidence of disease 
is low, few well-designed, randomized trials have evaluated treatment dosage and duration. Newer 
oral antiviral agents are emerging as alternatives to high-dose intravenous acyclovir, avoiding 
the need for inpatient intravenous treatment. Drug resistance is uncommon but may also be 
difficult to identify. Antiviral drugs have few side effects, but special attention needs to be paid 
to patients who have underlying renal disease, are pregnant or are immunocompromised.
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Introduction
Acute retinal necrosis (ARN) is an uncommon, but potentially blinding, uveitic 
syndrome characterized by progressive peripheral necrotizing retinitis.1 The American 
Uveitis Society diagnostic criteria (1994) defines ARN as a necrotizing retinitis with 
one or more foci that exhibits circumferential spread with evidence of occlusive 
vasculopathy, an inflammatory reaction in the anterior chamber and vitreous that is 
independent of the extent of retinal necrosis, age, gender and the immune status of 
the patient.2 It was first described by Urayama et al in 1971,3 but it was more than a 
decade later before a herpetic etiology was discovered and antiviral therapy became 
the mainstay of treatment.4 Today, ARN is recognized as being predominantly caused 
by varicella zoster virus (VZV) and herpes simplex virus types 1 and 2 (HSV-1, 
HSV-2), with some studies implicating cytomegalovirus (CMV) and Epstein-Barr virus 
(EBV).4–9 While the diagnosis of ARN is usually straightforward, much controversy 
surrounds its management. Debate continues on the benefit or otherwise of aspirin, 
corticosteroids, barrier laser and prophylactic vitrectomy.10–12 More fundamentally, there 
is a lack of consensus on the best antiviral regime; the “conventional regimen” derived 
more than 20 years ago was still used as gold standard in recent studies that looked at 
different aspects of ARN management such as the effect of prophylactic vitrectomy and 
intraoperative antiviral lavage11,12 This review focuses on the current understanding of 
acyclovir in the management of ARN. For completeness, we have also included other 
antiviral agents that have been reported in the literature to be effective.
Historical perspective
The clinical triad of acute panuveitis, occlusive retinal arteritis and peripheral retinal 
necrosis was first described in Japanese literature as Kirisawa’s uveitis in 1971.3 Clinical Ophthalmology 2010:4 12
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Later, Martenet in 1976 and Young and Bird in 1978 coined 
the term ‘acute retinal necrosis’.13,14 Natural history studies 
demonstrated a very poor prognosis in the pre-acyclovir era. 
A review, which integrated 52 cases of ARN reported in 11 
series, found that 75% of affected eyes progressed to retinal 
detachment. Only 22% of these eyes achieved anatomic reat-
tachment and only 28% had a final visual acuity of 20/200 
or better.10
In 1982 Culbertson, Blumenkranz and associates studied 
the histopathology and electron microscope findings of an 
eye enucleated from a patient with acute retinal necrosis.4 
Histology revealed eosinophilic intranuclear inclusions in 
retinal cells and electron microscopy demonstrated a herpes 
group virus in all layers of affected retina. They confirmed 
these findings, identifying VZV as the cause, in two support-
ing cases published in 19865 and in the same year reported 
their initial experience with intravenous acyclovir in the treat-
ment of ARN. Thirteen eyes of 12 patients were treated with 
intravenous acyclovir 10 mg/kg 3 times daily for an average 
of 10.9 days. Initial and complete regression of retinal lesions 
was noted on average 3.9 days and 32.5 days respectively after 
treatment initiation. No eye developed new retinal lesions or 
progressive optic nerve involvement 48 hours or more after 
treatment initiation. No systemic or ocular side effects from 
treatment were noted.15
Crapotta et al subsequently reported treating 13 eyes 
of 12 patients with the same intravenous acyclovir regime 
for 8 to 21 days followed by oral acyclovir (400 to 800 mg 
5 times daily) for at least 2 weeks after intravenous acyclovir 
treatment was discontinued. In 11 of the 12 patients there 
was complete resolution of active lesions within 21 days 
of initiation of antiviral therapy. Two patients developed 
reactivation after resolution 2 and 5 weeks after cessation 
of oral acyclovir which resolved after recommencement of 
acyclovir. Final visual acuity was 20/40 or better in 6 eyes 
and 20/400 or better in 12 eyes. No patient developed 
bilateral disease over a median follow up of 9.5 months.16 
In 1991, Palay et al reviewed the course of 54 patients 
who had unilateral ARN at initial examination. Thirty-one 
patients were treated with intravenous acyclovir, whereas 
23 were not treated with acyclovir. Two years after initial 
onset, 25% of the group treated with acyclovir developed 
ARN in the fellow eye compared with 65% of the group not 
treated with acyclovir.17
From these early papers derives the standard treatment for 
ARN detailed in current ophthalmic texts. The recommended 
regime is intravenous acyclovir 10 mg/kg every 8 hours 
(or 1500 mg/m2) per day for 5 to 10 days, followed by oral 
acyclovir 400 to 800 mg 5 times daily for an additional 6 to 
12 weeks. Six weeks was decided as the minimum duration 
of subsequent oral therapy because second eye involvement 
typically occurs within the first six weeks. However, although 
this is considered the traditional treatment, no prospective 
studies have investigated the optimal duration of intravenous 
treatment, timing of switching to oral therapy, or ideal total 
treatment duration.
Recently,  Kawaguchi  et  al  have  recommended 
commencing intravenous acyclovir at a dose of 15 mg/kg 
three times daily, provided the patient has no renal impair-
ment.18 They argued that ocular lesions in patients with 
ARN due to VZV often tend to be more severe and progress 
more rapidly than those associated with HSV. Therefore 
they initiate acyclovir treatment at a higher dose until the 
causative virus is identified by polymerase chain reaction 
(PCR) on ocular fluid. If the PCR results confirm HSV as the 
causative virus, the dosage is reduced to 10 mg/kg 3 times 
daily. Intravenous therapy is followed by 6 weeks of oral 
antiviral therapy. They question the efficacy of using oral 
antiviral agents alone for the treatment of severe cases of 
ARN. Others have advocated supplementing intravenous 
acyclovir therapy with intravitreal injections of ganciclovir 
or foscarnet for severe cases of ARN.19–21 Ganciclovir and 
foscarnet injections and ganciclovir implants have been 
shown to be effective in treating progressive outer retinal 
necrosis (PORN),22 a more fulminant form of retinal necrosis 
due to VZV or HSV which occurs in immunocompromised 
patients such as AIDS,23,24 organ transplantation,25 leukemia26 
and non-Hodgkin lymphoma.27
Conversely, there are an increasing number of ophthalmic 
centers that are switching to oral therapy alone. Proponents 
reason that the current standard treatment of ARN was 
based on anecdotal evidence and predated the availability 
of oral valacyclovir and famciclovir which have superior 
plasma bioavailability compared with oral acyclovir. In 
1997, Figueroa et al reported a case of ARN unresponsive to 
intravenous acyclovir that was successfully treated with oral 
famciclovir.28 In 2002, Aslanides et al described three cases 
of ARN who were treated with oral valacyclovir 1 g 3 times 
daily for 3 weeks (2 patients) or 3 months (1 patient). No 
new lesions appeared 3 to 4 days after initiation of treatment 
and complete resolution was achieved by 2 months. Final 
visual acuities were 20/25, 20/30 and 20/40 and there was 
no recurrence of disease or fellow eye involvement over a 
6- to 12-month follow-up period.29 Emerson et al described 
similar success with 2 patients treated with oral valacyclovir 
(1 g 3 times daily) and 2 patients treated oral famciclovir Clinical Ophthalmology 2010:4 13
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(500 mg 3 times daily) although they emphasized that all 
4 cases were relatively indolent.30
The largest consecutive case series of patients with ARN 
treated solely with oral antiviral therapy was reported by 
Aizman et al in 2007.31 Ten eyes of 8 patients were treated 
with either oral valacyclovir 1 g 3 times daily (4 eyes) or 
oral famciclovir 500 mg 3 times daily (6 eyes) for a mean 
of 12 weeks and then the dose was tapered over a mean of 
13 weeks. One patient with bilateral ARN received a single 
intravitreal injection of foscarnet 2.4 mg/0.1 mL in the more 
severely involved eye. All 10 eyes had complete resolution 
of retinitis. Initial regression of retinitis was observed on 
average 6.3 days after initiation of treatment and required 
an average of 17 days for complete resolution. This com-
pares favorably with the results of intravenous acyclovir 
treatment reported by Blumenkranz et al who noted initial 
regression 3.9 days into treatment and complete resolution 
32.5 days after commencing treatment.15 Final visual acu-
ity was improved in 6 eyes, stable in 2 eyes and worse in 2 
eyes. One patient, on a maintenance dose of oral acyclovir 
400 mg twice daily for impaired immunity, developed a 
recurrence 11 months after the initial episode that resolved 
with recommencement of famciclovir. None of the 4 patients 
with initially unilateral disease developed fellow eye 
involvement.
In summary, due to the rarity of the disease and a lack 
of prospective clinical trials, there is no current consensus 
on the optimal treatment of ARN. Many authors still employ 
the traditional regime of intravenous acyclovir 10 mg/kg 
3 times daily for 5 to 10 days followed by oral acyclovir 400 
to 800 mg 5 times daily for at least 6 weeks. However, oral 
antiviral therapy alone is being increasingly adopted as an 
alternative. This remainder of this review will explore the 
mode of action, antiviral activity, pharmacokinetics and toler-
ability of the various antiviral agents to determine evidence 
for the various regimes.
Acyclovir
Pharmacology: mechanism of action
The antiviral effect of acyclovir was first described in 1977 
and was the result of a systematic search for a drug capable 
of exploiting the fact that viral-infected cells are induced 
by the virus to produce thymidine kinase.32 The affinity of 
acyclovir for virus-specific thymidine kinase is approximately 
200 times greater than its affinity for cellular thymidine 
kinase. Hence, intracellular acyclovir is rapidly and prefer-
entially phosphorylated by virus-specific thymidine kinase 
to form acyclovir monophosphate, creating a concentration 
gradient favoring uptake by infected cells compared with 
non-infected cells. Host cellular enzymes then complete the 
phosphorylation to acyclovir triphosphate, the active form of 
the drug. Acyclovir triphosphate inhibits viral replication by 
acting as a competitive substrate for viral DNA polymerase, 
and its subsequent incorporation into the viral DNA chain 
results in obligate chain termination. Replication of HSV is 
inhibited at concentrations up to 3000-fold lower than those 
required to inhibit mammalian cellular functions. Acyclovir 
is therefore highly specific for herpes-infected cells and, 
as it selectively converted to its active form in virus-infected 
cells, it is non-toxic to uninfected cells.
Antiviral activity
Although acyclovir displays inhibitory activity against all 
herpesviruses in vitro, great variations in sensitivity exist 
among individual subtypes. The dose of acyclovir required 
to reduce HSV-1 viral plaques by 50% in tissue culture 
(Inhibitory concentration 50%, IC50), is less than 0.1 µM for 
most and 2.0 µM in rare, resistant strains.33 Varicella-zoster 
virus and EBV have intermediate IC50 values that range from 
1.3 to 20.6 µM (mean 3 to 4 µM) and 0.3 to 25.0 µM,34,35 
respectively, while IC50 values for CMV , the least sensitive 
of the herpesvirus group, have been reported to be as high 
as 200 µM.35
Pharmacokinetics
Gastrointestinal absorption of acyclovir is slow, highly vari-
able and incomplete with an oral bioavailability of 15% to 
30%.36 Peak plasma concentrations (Cmax) are achieved 1.5 
to 2.5 hours after oral administration and a short plasma 
half-life of 3 hours necessitates frequent (5 times per day) 
dosing. Whereas, plasma concentrations of 10 to 20 µg/mL 
can be achieved with intravenous acyclovir administration 
of 5 to 10 mg/kg, regular oral doses of 200 to 800 mg only 
yield concentrations of 0.6 to 1.6 µg/mL. Approximately 
15% of acyclovir is protein-bound. It achieves widespread 
tissue distribution, resulting in CSF levels 50% of that of 
plasma. A small fraction of acyclovir is metabolized by the 
liver, and its major metabolite accounts for only about 14% 
of an oral dose. The primary route of elimination of acyclovir 
is through the kidneys with 62% to 91% of acyclovir being 
excreted unchanged in the urine via both tubular secretion 
and glomerular filtration.37,38
intraocular penetration of acyclovir
Few studies looked specifically into the intravitreal pen-
etration of acyclovir. Early studies only focused on the Clinical Ophthalmology 2010:4 14
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inhibitory concentrations for HSV-1 and HSV-2 in the 
aqueous,39,40 and hence their conclusions may not be 
extrapolated when we now realize ARN can be caused by 
viruses that have a higher IC50. One report has shown when 
given intravenously at 13 mg/kg 3 times daily, intravitreal 
acyclovir concentrations of 17.9 µM may be achieved.41 
This is therapeutic for most strains of ARN-related viruses. 
In a study by Hung et al mean concentration in the aqueous 
humor after 5 doses of 400 mg oral acyclovir 24 hours before 
elective cataract surgery was found to be 3.26 µM, a level he 
concluded as therapeutic for HSV-1.42 From the limited data 
available, one may conclude that higher intraocular levels 
of acyclovir can be achieved when given intravenously than 
orally, but neither treatment provide complete coverage for 
all known strains of viruses that are able to cause ARN. 
This may translate into the treatment-resistant cases and 
the evolution for combined antiviral treatment necessary 
in subsequent case reports.
viral resistance
Despite the widespread use of acyclovir for three decades, 
the incidence of acyclovir-resistant HSV strains among 
immunocompetent persons has remained low, ranging from 
0 to 0.6%.43–45 Resistance in immunocompromised patients in 
general is also uncommon with a prevalence of approximately 
5%. However, prevalence of HSV resistance in allogeneic 
bone marrow transplant patients has been reported to be as 
high as 30%.43–45 Resistance to acyclovir is associated with 
mutations on either viral thymidine kinase or DNA poly-
merase.46 In 95% of cases, acyclovir resistance is due to a 
mutation in the thymidine kinase gene as this enzyme is not 
essential for viral replication. Strains resistant to acyclovir 
are virtually always cross-resistant to other thymidine kinase-
dependent drugs such as penciclovir and famciclovir. These 
strains will be sensitive to foscarnet or cidofovir as these 
drugs inhibit viral DNA polymerase but they do not depend 
on thymidine kinase.47
Valacyclovir
Pharmacology: mode of action  
and antiviral activity
Valacyclovir is the oral prodrug of acyclovir and has the same 
mode of action as acyclovir.
Antiviral activity
Valacyclovir is the oral prodrug of acyclovir and has the same 
antiviral activity as acyclovir.
Pharmacokinetics
Valacyclovir, the L-valyl ester of acyclovir, creates a substrate 
for active transport mechanisms in the human intestine. After 
absorption, valacyclovir undergoes rapid and virtually com-
plete first pass metabolism in the intestine and liver to form 
acyclovir and the essential amino acid L-valine.48 This process 
is cytochrome P450 independent. The distribution, intracellular 
kinetics, metabolism and excretion of acyclovir once it enters 
the systemic circulation are identical whether it is adminis-
tered as oral valacyclovir or oral or intravenous acyclovir.
The increased uptake and rapid hydrolysis of valacyclovir 
to acyclovir results in significantly greater systemic levels 
of acyclovir following oral valacyclovir ingestion compared 
with oral acyclovir ingestion. The mean bioavailability of 
acyclovir following a single 1 g dose of valacyclovir in 
healthy adult volunteers is 54.2%.49 A similar bioavailability 
of acyclovir after valacyclovir of 45% to 48% was found in 
children.50 Single- and multiple-dose studies have demon-
strated 3- to 5-fold increases in bioavailability of valacyclovir 
relative to oral acyclovir.
Administration of valacyclovir 250 mg 4 times daily 
results in acyclovir Cmax and area under the concentration-time 
curve (AUC) values comparable to oral acyclovir 800 mg 
5 times daily.51 Daily acyclovir AUC values for valacyclo-
vir at a dose of 1000 mg 3 times daily are similar to those 
obtained with intravenous acyclovir 5 mg/kg administered 
3 times daily. Valacyclovir 2000 mg 4 times daily produces 
a daily AUC of 109 µg ⋅ h-1 mL-1 which was identical to that 
achieved by intravenous acyclovir 10 mg/kg three times daily 
(AUC of 107 µg ⋅ h h-1 mL-1).52
intraocular penetration of valacyclovir
In a study by Huynh et al the intravitreal concentrations 
of acyclovir in 10 uninflamed eyes of 10 subjects before 
elective pars plana vitrectomy after oral valacyclovir 1gram 
three times daily was measured. A mean vitreous acyclovir 
concentration of 1.03 µg/mL and a vitreous-to-serum con-
centration ratio of  0.24, ie, 25% of serum levels was found.53 
Although the dose used in this study (1 g 3 times daily) was 
proven effective in other case reports,30,31 vitreous acyclovir 
concentration was lower than a similar report that measured 
CSF acyclovir concentrations.54 The authors attributed this 
to the timing of sampling that might have led to an underes-
timation of the true peak concentration, and has suggested 
that the levels may be higher in ARN where there is a 
breach of the blood retinal barrier. More data are needed to 
elucidate the peak intravitreal levels following valacyclovir 
administration.Clinical Ophthalmology 2010:4 15
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Other anti-viral drugs used  
in management of ARN
Famciclovir
Pharmacology: mode of action
Famciclovir is the oral prodrug of penciclovir.55 Like 
acyclovir, penciclovir is preferentially phosphorylated 
by virus-specific thymidine kinase to form penciclovir 
monophosphate. Host cellular enzymes then complete the 
phosphorylation to penciclovir triphosphate, the active form 
of the drug, which acts as a competitive substrate for viral 
DNA polymerase. Incorporation of penciclovir triphosphate 
into the viral DNA chain does not prevent additional bases 
from being added but renders the process inefficient and 
replication eventually ceases, a process known as conditional 
chain termination. The affinity of viral thymidine kinase for 
penciclovir is 100-fold greater than that for acyclovir but the 
penciclovir triphosphate form is less effective than acyclovir 
triphosphate as an inhibiter of HSV DNA polymerase.
Antiviral activity
The IC50 values obtained for penciclovir (administered orally 
as the prodrug famciclovir) have been shown to be similar 
to those achieved with acyclovir (administered orally as the 
prodrug valacyclovir). An addition, it was shown famciclovir 
is able to reduce viral load at the ganglia level in mice, thereby 
reducing recurrence. The underlying mechanism for this 
effect is unknown.56,57
Pharmacokinetics
Famciclovir is rapidly and efficiently converted, via hydrolysis 
in the intestinal wall and oxidation in the liver, to penciclovir 
and acetic acid. The mean bioavailability of penciclovir fol-
lowing a single dose of famciclovir is 77% and peak serum 
concentrations are achieved within one hour.55 Penciclovir 
is only 20% protein bound and it achieves widespread tis-
sue distribution. No significant metabolism occurs and 
approximately 60% is excreted unchanged by the kidneys. 
Its elimination half-life is 2 hours in healthy adult volunteers 
but prolonged intracellular half-life has been demonstrated 
in cells infected with VZV (9 to 14 hours), HSV-1 (10 hours) 
and HSV-2 (20 hours).58 Patients with hepatic insufficiency 
have 44% reduction in penciclovir mean plasma concentra-
tion compared to controls. Chong et al found a mean intra-
vitreal penciclovir concentration of 1.21 µg/mL following 
4 oral doses of famciclovir 500 mg. They concluded this is 
therapeutic for nonresistant restrains of HSV-1, HSV-2 and 
VZV (with IC50 of 0.04 to 0.06 µg/mL, 0.05 to 2.1 µg/mL 
and 0.1 to 5.0 µg/mL, respectively.59
valganciclovir
Pharmacology: mode of action
Valganciclovir is the oral prodrug of ganciclovir and has the 
same mode of action as ganciclovir.
Antiviral activity
The efficacy of valganciclovir against CMV retinitis was 
proven in a multicenter trial.60 However, evidence for its 
use in acute retinal necrosis is scant. Savant et al described 
a case of VZV ARN in an immunocompetent woman who 
was successfully treated with valganciclovir. She was given 
valganciclovir 900 mg twice daily induction for 3 weeks fol-
lowed by once daily maintenance for 2 weeks. Oral acyclovir 
400 mg three times daily was continued for 3 months.61 In 
another report, Cottet et al treated a case of HSV-2 ARN with 
intravenous acyclovir 10 mg/kg 3 times daily for 4 weeks, oral 
valganciclovir 450 mg twice daily for 2 weeks and a single 
intravitreal injection of ganciclovir 2000 µg. Oral acyclovir 
was continued for 3 months. The patient had a final vision 
of 1.0 bilaterally and undetectable viral DNA in aqueous at 
month 10.62
Pharmacokinetics
Valganciclovir is the L-valyl ester prodrug of ganciclovir 
with enhanced bioavailability. It is hydrolyzed in the intes-
tinal tissues and hepatocytes to produce ganciclovir.63 After 
phosphorylation, the substrate of ganciclovir competitively 
inhibits deoxyguanosine triphosphate binding to DNA poly-
merase. This results in inhibition of viral DNA synthesis.
The bioavailability from valganciclovir is increased 
10-fold compared to oral ganciclovir (60% with food).64 
An oral dose of 900 mg achieves ganciclovir AUC similar 
to that with 5 mg/kg intravenous ganciclovir dosing. The 
elimination half-life of ganciclovir is 4.08 hours. This can be 
prolonged in patients with renal impairment. It is excreted 
in urine in forms of ganciclovir.64
Safety and tolerability of antivirals 
in the management of acute retinal 
necrosis
The specificity of acyclovir for virally infected cells and its 
selective conversion to the active form within virally infected 
cells results in favorable clinical safety and tolerability pro-
files. Renal impairment is the most common side effect and 
is related to its renal excretion and poor water solubility.65 It 
can be in the form of intraluminal crystal precipitation66 or 
interstitial nephritis.67 Rapid intravenous bolus administra-
tion increases the risk although oral acyclovir can also cause Clinical Ophthalmology 2010:4 16
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acute renal failure in the setting of severe volume depletion 
and excessive oral dosage.68
The incidence of renal impairment associated with acyclovir 
has been reported to range from 12% to 48%.65,68 It is usually 
asymptomatic, but some patients may complain of nausea 
or vomiting and flank or abdominal pain. Urinalysis reveals 
hematuria and pyuria. Renal function usually recovers after 
drug cessation and volume resuscitation. Hemodialysis may 
be indicated when renal failure is severe. A reduction of 
acyclovir dose is essential in patients with underlying renal 
insufficiency and calculation of the appropriate acyclovir 
dose based on the estimated glomerular filtration rate will 
significantly reduce the risk of acute renal failure.70
Neurotoxicity occurs less frequently. Patients on con-
tinuous ambulatory peritoneal dialysis are at particular risk 
because it is not effective in the removal of plasma acyclovir.71 
Clinical manifestations can sometimes mimic central nervous 
system involvement by herpesvirus and include lethargy, 
delirium, agitation, seizures, hallucinations and coma. Hemo-
dialysis may sometimes be indicated.
Pregnancy
Experience has been gained in the use of acyclovir and 
valacyclovir during pregnancy for potentially severe con-
ditions such disseminated HSV , varicella pneumonia, and 
severe primary genital herpes. The International Acyclovir 
Pregnancy Registry has monitored the birth outcome of more 
than 1200 women exposed to oral or intravenous acyclovir 
during pregnancy. In its latest report, the observed birth defect 
rate was 3.2% (95% confidence interval, 2.0% to 5.0%).72 
This is comparable to that of the general population. The 
authors concluded that acyclovir and valacyclovir exposure 
during pregnancy does not increase the rate of birth defects. 
Acyclovir and valacyclovir both belong to Pregnancy Drug 
Category B, meaning there is no clear evidence of risk in 
humans although there are no controlled studies to docu-
ment safety.
immunocompromised
Although usually a disease of immunocompetent persons, 
ARN can also occur in immunocompromised individuals. 
Aside from an increased prevalence of HSV resistance,43 no 
specific issues have been identified regarding acyclovir treat-
ment in this population. Of note is the well-known association 
of herpetic encephalitis with ARN. In a retrospective report 
involving 52 patients with ARN, Vandercam et al identified 7 
who had preceding herpetic encephalitis. The immunocom-
promised patients all had bilateral disease caused by VZV . 
The authors concluded that herpetic encephalitis is a risk fac-
tor for ARN, and treatment may improve the outcome at least 
for the contralateral eye.73 The standard treatment for herpetic 
encephalitis is intravenous acyclovir 10 mg/kg 3 times daily 
for at least 10 days.74 Shorter duration of treatment is associ-
ated with occasional relapse with acyclovir-sensitive HSV .75 
There is insufficient evidence to support valacyclovir as an 
equally effective agent to date.
Three randomized, controlled trials (RCTs) and one 
open-label study demonstrated the long-term safety of oral 
valacyclovir for suppression of recurrent genital HSV infec-
tion. A total of 3050 patients (1062 immunocompromised) 
were enrolled in the studies and 2206 received valacyclovir 
250 to 1000 mg/day for up to one year.76 Pooled together, the 
incidence of adverse events were 32% and 31% for valacy-
clovir and acyclovir respectively, this compares to 24% in the 
placebo group. The most frequent of them were headache, 
infectious illnesses (influenza, rhinitis, sinusitis), and nausea. 
These were regarded likely to be concurrent illnesses rather 
than a genuine adverse event, and given the potential con-
sequences of ARN, the risks will probably be offset by its 
benefits. There seems to be no apparent relationship between 
total daily exposure to valacyclovir and the frequency or 
severity of adverse events. Nor was the long term use of 
valacyclovir associated with disturbances in hematological 
or biochemical profiles.76 Serious adverse events in immu-
nocompetent patients that were believed to be attributed to 
the drug occurred in 3 valacyclovir recipients (leucopenia, 
hepatitis and headache) and 2 acyclovir recipients (myas-
thenia and suicidal ideation). Manifestations resembling 
thrombotic microangiopathy have been reported in clinical 
trials evaluating high doses of valacyclovir (8000 mg/day) 
administered for prolonged periods (months to years) for 
prophylaxis of CMV infection and disease, particularly in 
persons with HIV infection. There were no reports of throm-
botic microangiopathy among the 3050 subjects evaluating 
valacyclovir for suppression of genital herpes. The implica-
tion is occurrence of thrombotic microangiopathy is restricted 
to severely immunosuppressed subjects receiving high doses 
of valacyclovir.77
In both the single- and multiple-dose studies carried out 
in healthy volunteers, the safety profile of valacyclovir was 
excellent. Adverse experiences considered associated with 
study medication included headaches and gastrointestinal 
complaints. In a study that evaluated that the pharmacoki-
netics of multiple-dose valacyclovir in a group of 65- to 
83-year-old volunteers, Wang et al found higher Cmax and 
mean AUC values when compared to younger subjects; Clinical Ophthalmology 2010:4 17
Antiviral selection in acute retinal necrosis Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
these differences were attributed to the reduced creatinine 
clearance in the geriatric population. Valacyclovir was well 
tolerated in this population, with no serious adverse events 
reported.51
Hoglund and associates postulated that the lower peak 
plasma concentrations associated with oral therapy may 
reduce the risk of renal adverse events compared with intra-
venous acyclovir administration.78
In a large study of patients taking valacyclovir 1 g 3 times 
daily, headache (17%) and nausea (14%) were the most 
common complaints. Another study of 60 healthy human 
volunteers taking valacyclovir 2 g 4 times daily demonstrated 
no serious adverse events, with subjects reporting headaches 
and gastrointestinal disturbances.79 The authors suggested 
that in comparison to intravenous ACV , lower peak plasma 
acyclovir concentrations resulting from administration of oral 
valacyclovir may minimize the risk of renal adverse effects 
while providing similar clinical efficacy.52
The limit of the administration of high dosage valacy-
clovir is mostly the renal and central nervous system (CNS) 
toxicity of the drug that can be avoided by adequate hydra-
tion and dose adjustment to creatinine clearance. These high 
valacyclovir dosages have been indeed well tolerated when 
prescribed to kidney transplant recipients for the prophylaxis 
of CMV disease, with only slight excess in CNS adverse 
effects such as hallucination and confusion.80
Famciclovir was well tolerated in adult clinical trials 
for HSV and VZV infections. The most common adverse 
events were headache (9.3%), nausea (4.5%) and diarrhea 
(2.4%).81 These reported adverse events were not serious 
and were comparable in incidence to the placebo group. No 
differences in adverse events were noted between acyclovir 
and famciclovir. Famciclovir is not recommended for use 
in pregnancy.
Compared to acyclovir, ganciclovir has similar activity 
against HSV and VZV . The enhanced anti-CMV activity is 
attributable to the lack of a hydroxyl group on the acyclic 
side chain. Nonetheless, this modification is associated with 
potentially serious side effects such as blood dyscrasias and 
fertility problems. Evidence from animal studies has shown 
ganciclovir to be teratogenic, mutagenic and carcinogenic.82 
Contraceptive precautions for all patients may thus be 
required.
Summary
The rarity of ARN has hindered a development of RCTs in 
properly evaluating an ideal treatment protocol. The multiple-
viral etiology and need for PCR for proper identification 
can all contribute to potential delays in diagnosis, and the 
prescription of empirical treatment that has been based on 
past case reports. Advances in the use of novel agents have 
been limited to cases in which the causative virus is known 
to respond better to one agent (valganciclovir for CMV), 
or when conventional treatment has failed (famciclovir for 
acyclovir-resistant ARN). Safer methods to obtain intraocu-
lar samples for rapid viral identification, such as aqueous 
sampling rather than vitreous biopsy,83 may allow prompt 
initiation of effective treatment.
Acyclovir and famciclovir, whether in the conventional 
intravenous or the oral-prodrug forms, have been proven to 
achieve therapeutic concentrations in the vitreous at conven-
tional doses. The choice would then be decided on experi-
ence and safety profile. Acyclovir, and its newer analogue 
valacyclovir, remains the drug favored by most because of 
its efficacy and safety. Foscarnet and valganciclovir are usu-
ally recommended for retinitis in the immunocompromised, 
where CMV infection predominates. Intravenous and intra-
vitreal ganciclovir has been used in case reports.84,85
What remains to be elucidated is the exact duration of 
treatment. Clinical examination has been the gold standard 
in monitoring treatment response and dosage titration. 
Newer methods, such as quantitative assays for viral DNA, 
may provide additional information and guide treatment in 
the future.
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Appendix 1  
Summary of the different antivirals used in acute retinal necrosis (ArN)
  Acyclovir Valacyclovir Famciclovir Foscarnet Valganciclovir
Dose iv 10–13 mg/kg 3 times  
daily for 5–10 days, then  
400–800 mg 5 times  
daily for 6–8 weeks po
1–2 g 3 times daily  
for 6–8 weeks
500 mg 3 times daily po  
for 12 weeks, followed  
by taper for 13 weeks
2.4 mg/0.1 mL  
intravitreal as initial  
treatment
1 g 3 times daily po  
900 mg twice daily  
3 weeks induction, then  
900 mg daily for 2 weeks   
before switching to oral  
acyclovir
Use Current standard emerging standard  
because of comparable  
AUC but lower peak  
concentrations, which  
translates to safer profile
Acyclovir resistance Systemic treatment  
contraindicated, one  
case of childhood  
HSv-2 ArN
As substitute to  
existing regimen
Adverse effects CNS toxicity: lethargy,  
delirium, seizures, renal  
failure
Hemolytic uremic  
syndrome, thrombotic  
thromboycytopenic  
purpura (in  
immunocompromised  
patients 8 g/day)
Minimal Similar  
to placebo
Nil reported when  
given intravitreally
Myelotoxicity, sterility,  
CNS abnormalities
Abbreviations:   AUC, area under the concentration-time curve CNS, central nervous system; HSv, herpes simplex virus; PO, by mouth; iv, intravenous.